About the Event

This 3 CME hour live virtual update is designed for clinicians caring for patients with obesity, type 2 diabetes, and metabolic disease. Session 1 (2 CME) — Pipeline, Indications & Regulation. Covers newly filed obesity pharmacotherapies (retatrutide, CagriSema, orforglipron, maridebart, cafraglutide), maturing data on muscle preservation from the BELIEVE and COURAGE trials, cardiovascular and indication outcomes, the recent setmelanotide approval for acquired hypothalamic obesity, and the current FDA regulatory landscape on compounded GLP-1 medications. Session 2 (1 CME) — Environmental & Brain Dimensions. Examines how endocrine-disrupting chemicals (BPA, BPS, DEHP) link metabolic dysfunction to dementia risk through blood-brain barrier disruption, impaired amyloid clearance, and glymphatic dysfunction. Provides practical patient counseling strategies and reframes diabesity care as an integrated brain-health intervention. By the end of the course, attendees will be able to discuss newly approved agents with confidence, integrate body composition and outcomes data into prescribing decisions, counsel patients on environmental exposures, and apply a brain-protective approach to metabolic care.

Continuing Medical Education Credit

The AAFP has reviewed Diabesity Update 2026: Pharmacology, Environment, and the Brain and deemed it acceptable for up to 3.00 Live AAFP Prescribed credit(s). Term of Approval is from 08/22/2026 to 08/22/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

What you'll learn

Describe newly filed pharmacotherapies (retatrutide, CagriSema, orforglipron, MariTide)

Apply muscle preservation evidence to individual patient decisions

Integrate cardiovascular and indication outcomes into prescribing

Counsel patients on endocrine disruptors and brain-health connection, and reframe obesity care as an integrated brain-health intervention

Meet the speaker

Emily Cooper, MD

Medical Director, Diabesity Institute

Dr. Cooper is the Medical Director of the Diabesity Institute, host of the Fat Science podcast, and Board-certified in both Family Medicine and Obesity Medicine. She has built a clinical framework that approaches obesity and type 2 diabetes as manifestations of metabolic feedback loop dysfunction rather than as primary diseases of body weight. Her CME teaching translates the underlying neuroendocrine biology into practical, evidence-based care for clinicians treating diabesity in primary care and specialty settings.